Incannex Healthcare Inc.

Incannex is a clinical-stage biopharmaceutical company developing oral fixed-dose combination therapies and psychedelic-assisted treatments for serious, chronic conditions. Its pipeline includes IHL-42X, an oral combination therapy in clinical development for obstructive sleep apnea, and PSX-001, a synthetic psilocybin treatment administered alongside psychotherapy for generalized anxiety disorder. The company is also evaluating IHL-675A, an oral combination targeting inflammatory conditions including rheumatoid arthritis. These investigational programs aim to provide alternative pharmacological treatments for patients who are underserved by existing care options.

The company operates clinical trials across sites in the United States and has conducted early-stage studies and collaborative research in Australia. It also participates in a joint venture operating a psychedelic-assisted therapies services clinic in Melbourne, Australia. The provided text mentions manufacturing partnerships in the United States but does not identify the location of the corporate headquarters.

Summary of the business section of Incannex Healthcare's latest annual report, written by StockData.

“As of June 30, 2026, we had twelve full-time employees, including eight in R&D and four in general management and administration.”